Today, Vertex Pharmaceuticals Inc. announced positive Phase 3 clinical trial data for Trikafta® (elexacaftor/tezacaftor/ivacaftor) in children 6-11 years old with cystic fibrosis.
Site Search
The Cystic Fibrosis Foundation has launched a new program that will fund 60 additional research coordinators to help speed the progress of CF clinical trials throughout its Therapeutics Development Network (TDN).
When there is more than one person with CF in your school, it is essential that they be kept a minimum of 6 feet (2 meters) apart from each other. Germs can spread as far as 6 feet through droplets released in the air when people cough or sneeze.
This morning, Vertex Pharmaceuticals announced the results from the Phase 3 clinical trials of ivacaftor (Kalydeco™) and lumacaftor (VX-809) in people with two copies of the F508del mutation.
A virtual program for current and recent college students who want to continue building new leadership, advocacy, and fundraising skills to make a difference on their campuses and beyond.
As children with cystic fibrosis transition toward greater independence at school and at home, they will also take greater responsibility in managing their disease.
There are two main types of clinical studies in CF research. Both are important to move research forward and provide the best outcomes for people with CF.
Clinical trials are critical to developing new treatments for CF. So, how exactly does an experimental drug become an approved therapy?
There have never been more opportunities to help develop new drugs for cystic fibrosis than there are today. When you are deciding whether to participate in a
When participating in a clinical trial, nothing is more important than your safety. We go the extra mile when it comes to protecting study volunteers.